This study evaluates the combined effect of botulinum toxin A (administered as Dysport® (Ipsen Pharmaceuticals)) and bracing in children with adolescent idiopathic scoliosis. Two thirds of patients will be treated with Dysport® and bracing, while the remaining patients will be treated with placebo and bracing.
Clinically determined idiopathic nature of scoliosis
Age 10-16 years
Risser stage 0,1,or 2
major curve of 20°-40°
Diagnosis of congenital scoliosis, neuromuscular scoliosis, or other "reason" for scoliosis - Previous surgery at any segment of the spine
Current need for surgery at any level of the spine
Treatment with any drug known to interfere with neuromuscular function
Any other medical condition, laboratory or diagnostic procedure finding that might preclude administration of BTX